U.S. Markets closed

Orexigen Therapeutics, Inc. (OREX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.94+0.07 (+2.44%)
At close: 4:00PM EDT
People also watch
  • The FOOL dumps on OREX -he is SHORT------OREX was $150.00-----2 years ago ----OREX is back on course , one large fund buy in -POW -up $2.00-------
  • OREX is the MOST needed drug in America ----Large Pharma could buy OREX and increase sales 200 % ---
  • Well this price action is sucking hard!
  • has anyone checked out GBTC???? Is that not the craziest thing you have ever seen?
  • (AXSM) Market Cap $92 M/Cash $55 M / 5x BIG Phase 3 programs in various indications targeting large Markets with first results in Q3 2017 =20 BAGGER ..FANTASTIC OPPORTUNITY !

    Undiscovered and massive undervalued Biotech Stock with lots of Big News on the way.This Stock is brutally undervalued with a Market cap of just $92 million and $55 million in cash .Founder and Ceo is the larget shareholder holding over 7 million shares (30%) more than 50% of O/S is owned by Insider and Institutions which is a great sign .

    This undiscovered stock could be the next 10 bagger gem if just one of their 5 ongoing Phase 3 programs is successful .GL

    Axsome (AXSM)

    Market-Cap: $92 Million
    Cash: $55 Million(cash runway into the first quarter of 2019.)

    Shares Out: 23.5 Million

    Anticipated Near-Term Clinical Milestones

    Clinical Trial Initiations: -- Phase 2/3 clinical trial of AXS-05 in AD agitation (2Q 2017)

    Clinical Trial Readouts:

    -- Phase 3 COAST-1 trial of AXS-02 in knee OA associated with BMLs, interim analysis (3Q 2017)

    -- Phase 3 CREATE-1 trial of AXS-02 in CRPS, interim efficacy analysis (4Q 2017)

    -- Phase 3 STRIDE-1 trial of AXS-05 in TRD, top-line data (1Q 2018)

    New Presentation May

    HUGE Pipeline targeting Billion Dollar Markets:

    AXS-05 Treatment Resistant Depression in Phase 3......Only 1 approved drug for TRD = unmet medical need. 3M patients in the U.S.

    AXS-05 Agitation in Alzheimer’s Disease in Phase 2/3.......No approved medication = unmet medical need. 2M patients in the U.S.

    AXS-02 Complex Regional Pain Syndrome (CRPS) in Phase 3 (Orphan+Fast Track Status).......No approved drug = high unmet need. 80,000 new cases per year in the U.S.

    AXS-02 Knee Osteoarthritis (OA) with Bone Marrow Lesions (BMLs) in Phase 3 (SPA & Fast Track).........7M patients in the U.S.

    AXS-02 Chronic Low Back Pain(CLBP) with Modic Changes (MCs) in Phase 3 ......1.6M patients in the U.S.

  • If you are looking to scalp $3.05 area is where it will go back up to about $3.75 ish
  • It is a wise father that knows his own child.http://dataunion.tistory.com/9054

    Orexigen Therapeutics NASDAQ $OREX Correlation Histogram
    X axis : Stocks Price Correlation Coefficient Y axis : Quantity of stocks Sep-2016 1,000 Day Parameter 2,830 NASDAQ Stocks Price Analysis This stock mode of correlation coefficient is 0.5 In other words, the correlation coefficient of the other stock
  • Earnings -GREAT---front loaded 90% of sales cost---sales will increase 10% per Q---Q4--up 20--30% UP------shorts -keep shorting --house gone--bank gone- wife gone--LOL
  • Guys how are the earnings ?
  • Chemo is a $100 Billion dollar industry and one tiny little company threatens to replace it all and every other therapy including radiation with a product that appears to really work far better than anything else EVER and even with very minimal side effects. In fact, at the end of a phase III ten year brain cancer trial where the average patient with chemo lives only 14 months, this new immune therapy has been responsible for more than 100 BRAIN CANCER PATIENTS STILL LIVING AFTER TEN YEARS. OVER 100!

    Fortunate investors will discover this tiny company before final phase III results are released soon.

    This appears to be the big breakthrough in cancer treatment that the world has been looking for for decades.

    Home - Northwest Biotherapeutics
    Home - Northwest Biotherapeutics
    Home - Northwest Biotherapeutics

    Home - Northwest Biotherapeutics
  • The National Institute for Health and Care Excellence has published draft guidelines turning down Orexigen’s weight loss pill Mysimba for routine NHS use.
  • $10 coming soon
  • Just looking at the technicals: Blow out volume bursting into 3's earlier in the year. Chase follow though to high 5's. pulled back into low 4's. last Q's earnings were a non event except management's desperate act to raise cash. ensuing sell off on medium low volume bottomed at mid 2's= shook out weak hands. now back into 3's with IWM beginning breakout as a tailwind due to ETF buying. No real sellers on the tape here!! I can see this pushing into upper 3's. With any news and another huge volume week then I see this puppy blowing into higher grounds.
  • They are quite obviously more eager to discuss Q1 results than they were Q4. The DTC campaign is a success.
  • miss lovely should change her name to miss wrongly
  • well, well, well
  • http://www.pharmatimes.com/news/nice_rejects_orexigens_weight-loss_pill_1192361

    NICE rejects Orexigen’s weight-loss pill - PharmaTimes
    The National Institute for Health and Care Excellence has published draft guidelines turning down Orexigen’s weight loss pill Mysimba for routine NHS use. - News - PharmaTimes
  • What do we have here? only thing left is 50 DMA
  • In case your keeping score, today was an 'outside' day with a slightly lower low and a slightly higher high price wise. Still not considered an up day. Fortunately it closed near its high but still is now ten days without an up day. Here's hoping it is tomorrow. Friday market is closed so we'd have to wait till next week for the up day (if not tomorrow). Good luck longs!
  • Another 'inside' day today again. Technically stock price is hanging in. Needs to start having some up days. We haven't had an up day in about 2 weeks...